IRIDEX announces acquisition of certain assets from RetinaLabs

IRIDEX Corporation (Nasdaq: IRIX) today announced that it has acquired certain assets from RetinaLabs, Inc., a privately held company based in Atlanta, Georgia. RetinaLabs develops and markets innovative retinal instrumentation used by ophthalmologists to perform vitreoretinal procedures in the operating room and the surgery center.

Pursuant to the terms of the purchase agreement, IRIDEX has acquired substantially all of the assets of RetinaLabs, including its existing product family together with certain additional intellectual property that IRIDEX anticipates incorporating into future products. The purchase price for the acquired assets consisted of $250,000 in cash consideration and 115,000 unregistered shares of IRIDEX common stock issued at closing, and an earn-out. The earn-out is tied to future revenues and could result in additional cash and share consideration to RetinaLabs based on the future performance of the acquired products and intellectual property. Other terms of the transaction were not disclosed.

"We have previously stated that our growth strategy will consist of organic initiatives supplemented by acquisitions. This acquisition represents a step towards executing this strategy and we expect it to be accretive in the near term. The majority of the products we acquired from RetinaLabs are consumables with strong gross margins. These products will be sold through our existing sales channels and we expect that sales of these products will add to our profitability," said Theodore A. Boutacoff, President and Chief Executive Officer of IRIDEX. "In addition, Frank Tighe, President of RetinaLabs, will join IRIDEX as Vice President of Vitreoretinal Instrumentation."

"RetinaLabs has a history of working with ophthalmology luminaries, notably Dr. Eugene de Juan and Dr. Mark Humayun for new product development.  We believe this acquisition is illustrative of how we can strategically augment our internal R&D to generate an ongoing flow of innovative products that provide value to our customers and enhance IRIDEX's growth."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakdancer’s scalp mass removed after years of headspin injuries